KromaTiD’s dGH and Pinpoint FISH technologies will offer our customers clear advantages in the fields of gene target discovery and mutation validation with great potential for clinical applications, says Mr. Takashi Endo, CEO of Tokyo Future Style, Inc.
Fort Collins, CO (PRWEB) May 18, 2015
“We are excited to be working with KromaTiD because we believe that their novel genomic technology will be attractive to our customers and the Japanese market. KromaTiD’s dGH and Pinpoint FISH technologies will offer our customers clear advantages in the fields of gene target discovery and mutation validation with great potential for clinical applications, says Mr. Takashi Endo, President and CEO of Tokyo Future Style, Inc.
Based on a proprietary chromatid-specific imaging platform, directional Genomic Hybridization (dGH™) assays are the only imaging assays capable of determining DNA sequence, location and orientation data in a single test. With these three dimensions of high-resolution data, dGH assays are unique in their ability to detect the widest range of disease-causing genetic rearrangements, including chromosomal inversions and translocations—mutations usually missed by other genomic tools, including today’s advanced sequencing technologies.
“Tokyo Future Style has a very focused approach to the Japanese market that we feel makes them a great fit for selling our products and services. We look forward to a productive relationship,” says Alex Vodenlich, KromaTiD’s Chief Executive Officer.
KromaTiD's commercial offering includes kits & assays for detecting known mutations and for discovering new disease-causing mutations, custom assays for tracking rearrangements to genes and for validating results from sequencing and arrays. KromaTiD also offers it customers affordable assay and sample processing services that deliver high quality data in a timely fashion.
KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating new products for genetic disease research, mutation detection and chromosome analysis. KromaTiD’s patented directional Genomic Hybridization (dGH™) chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations. KromaTiD develops and markets dGH technology under license from Colorado State University.
Tokyo Future Style, Inc. is an international trading and marketing company located in the Tokyo area. TFS mission is to market and distribute novel new products and services from foreign biotech companies to academic and government institutions, and to research and development laboratories of major pharmaceutical, diagnostic and biotech companies in Japan.